Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

In vitro cross-resistance profile of nucleoside reverse transcriptase inhibitor (NRTI) BMS-986001 against known NRTI resistance mutations.

Antimicrobial agents and chemotherapy - 1 Nov 2013

Li Zhufang, Terry Brian, Olds William, Protack Tricia, Deminie Carol, Minassian Beatrice, Nowicka-Sans Beata, Sun Yongnian, Dicker Ira, Hwang Carey, Lataillade Max, Hanna George J, Krystal Mark

Abstract excerpt

BMS-986001 is a novel HIV nucleoside reverse transcriptase inhibitor (NRTI). To date, little is known about its resistance profile. In order to examine the cross-resistance profile of BMS-986001 to NRTI mutations, a replicating virus system was used to examine specific amino acid mutations known to confer resistance to various NRTIs. In addition, reverse transcriptases from 19 clinical isolates with various NRTI...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Resistance, Multiple, Viral
Share to HIV-1

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to HIV Infections

Share to HIV Reverse Transcriptase

Share to Microbial Sensitivity Tests

Share to Mutagenesis, Site-Directed

Share to Reverse Transcriptase Inhibitors

Share to Thymidine

Source

Open in PubMed Open full text

Identifiers

PMID: 23979732
DOI: 10.1128/AAC.01195-13
PMCID: PMC3811251

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

In vitro cross-resistance profile of nucleoside reverse transcriptase inhibitor (NRTI) BMS-986001 against known NRTI resistance mutations.PMID 23979732Read ↗

Broad Nucleoside Reverse‐Transcriptase Inhibitor Cross‐Resistance in Human Immunodeficiency Virus Type 1 Clinical IsolatesSemantic proximity Read ↗

The nucleoside analog-resistant E89G mutant of human immunodeficiency virus type 1 reverse transcriptase displays a broader cross-resistance that extends to nonnucleoside inhibitors.Semantic proximity Read ↗

Highly drug-resistant HIV-1 clinical isolates are cross-resistant to many antiretroviral compounds in current clinical development.Semantic proximity Read ↗

The Emerging Profile of Cross-Resistance among the Nonnucleoside HIV-1 Reverse Transcriptase InhibitorsSemantic proximity Read ↗

Extent of cross-resistance between agents used to treat human immunodeficiency virus type 1 infection in clinically derived isolates.Semantic proximity Read ↗

Human immunodeficiency virus type 1 resistance or cross-resistance to nonnucleoside reverse transcriptase inhibitors currently under development as microbicides.Semantic proximity Read ↗

Cross-resistance patterns among HIV protease inhibitors.Semantic proximity Read ↗

Non-nucleoside reverse transcriptase inhibitor (NNRTI) cross-resistance: implications for preclinical evaluation of novel NNRTIs and clinical genotypic resistance testingSemantic proximity Read ↗

In vitro cross-resistance to doravirine in a panel of HIV-1 clones harbouring multiple NNRTI resistance mutations.Semantic proximity Read ↗

International perspectives on antiretroviral resistance. Nucleoside reverse transcriptase inhibitor resistance.Semantic proximity Read ↗

Activities of atazanavir (BMS-232632) against a large panel of human immunodeficiency virus type 1 clinical isolates resistant to one or more approved protease inhibitors.Semantic proximity Read ↗

Cross-resistance patterns in SARS-CoV-2 against 3CL protease inhibitors.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.